FDA Hosts Workshop on Benefits and Risks of Ovarian Cancer Maintenance Treatment

The Food and Drug Administration (FDA) hosts the first day of a workshop titled “Maintenance Treatment for Ovarian Cancer: Weighing Benefit and Toxicity in an Evolving Landscape” on Nov. 12. The workshop focuses on evaluating the benefits and potential toxicities of maintenance treatment for ovarian cancer amid an evolving treatment landscape.